USA: The STRIDE trial has demonstrated that semaglutide significantly enhances walking capacity in individuals with ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...